CytoDyn withdrew its pending Biologics License Application for the monoclonal antibody in HIV Friday, citing concerns involving the contract research organization managing its trials.  

Beset by clinical holds and the termination of its former company head, CytoDyn Inc. has tapped Cyrus Arman as its new president and he is expected to take over the reins of the company as chief executive officer and be added to the board of directors within six months.